Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Tebaldi

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 24, 2015
Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trialGabriele Crimi, Sergio Leonardi, Francesco Costa, et al.
Journal of the American College of Cardiology|October 29, 2013
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)Gianluca Campo, Matteo Tebaldi, Pascal Vranckx, et al.
European Journal of Heart Failure|February 20, 2020
Index of microcirculatory resistance assessment in patients with new diagnosis of left ventricular dilatation without significant coronary artery lesions: IMPAIRED pilot trialMatteo Tebaldi, Antonio Maria Leone, Simone Biscaglia, et al.
Journal of Cardiology Cases|December 12, 2018
Enhanced stent visualization systems during PCI: A case series and review of literatureSimone Biscaglia, Carlo Tumscitz, Matteo Tebaldi, et al.
Biologics : Targets & Therapy|August 27, 2009
Abciximab: a reappraisal of its use in coronary careMarco Valgimigli, Gianluca Campo, Matteo Tebaldi, et al.
Journal of Interventional Cardiology|November 9, 2020
Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept StudyMatteo Tebaldi, Simone Biscaglia, Domenico Di Girolamo, et al.
Journal of Clinical Medicine|April 30, 2021
Coronary Microvascular Dysfunction: PET, CMR and CT AssessmentElisabetta Tonet, Graziella Pompei, Evelina Faragasso, et al.
Platelets|June 2, 2011
Genetic determinants of on-clopidogrel high platelet reactivityGianluca Campo, Matteo Miccoli, Matteo Tebaldi, et al.
Cardiovascular Drugs and Therapy|June 9, 2022
Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic ReviewFederico Marchini, Graziella Pompei, Emanuele D'Aniello, et al.
JACC. Cardiovascular Interventions|March 24, 2012
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trialMarco Valgimigli, Matteo Tebaldi, Gianluca Campo, et al.
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 24, 2015
Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trialGabriele Crimi, Sergio Leonardi, Francesco Costa, et al.
Journal of the American College of Cardiology|October 29, 2013
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)Gianluca Campo, Matteo Tebaldi, Pascal Vranckx, et al.
European Journal of Heart Failure|February 20, 2020
Index of microcirculatory resistance assessment in patients with new diagnosis of left ventricular dilatation without significant coronary artery lesions: IMPAIRED pilot trialMatteo Tebaldi, Antonio Maria Leone, Simone Biscaglia, et al.
Journal of Cardiology Cases|December 12, 2018
Enhanced stent visualization systems during PCI: A case series and review of literatureSimone Biscaglia, Carlo Tumscitz, Matteo Tebaldi, et al.
Biologics : Targets & Therapy|August 27, 2009
Abciximab: a reappraisal of its use in coronary careMarco Valgimigli, Gianluca Campo, Matteo Tebaldi, et al.
Journal of Interventional Cardiology|November 9, 2020
Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept StudyMatteo Tebaldi, Simone Biscaglia, Domenico Di Girolamo, et al.
Journal of Clinical Medicine|April 30, 2021
Coronary Microvascular Dysfunction: PET, CMR and CT AssessmentElisabetta Tonet, Graziella Pompei, Evelina Faragasso, et al.
Platelets|June 2, 2011
Genetic determinants of on-clopidogrel high platelet reactivityGianluca Campo, Matteo Miccoli, Matteo Tebaldi, et al.
Cardiovascular Drugs and Therapy|June 9, 2022
Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic ReviewFederico Marchini, Graziella Pompei, Emanuele D'Aniello, et al.
JACC. Cardiovascular Interventions|March 24, 2012
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trialMarco Valgimigli, Matteo Tebaldi, Gianluca Campo, et al.
Pageof 12